These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37174060)

  • 1. Modeling Global Genomic Instability in Chronic Myeloid Leukemia (CML) Using Patient-Derived Induced Pluripotent Stem Cells (iPSCs).
    Telliam G; Desterke C; Imeri J; M'kacher R; Oudrhiri N; Balducci E; Fontaine-Arnoux M; Acloque H; Bennaceur-Griscelli A; Turhan AG
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs).
    Imeri J; Desterke C; Marcoux P; Telliam G; Sanekli S; Barreau S; Erbilgin Y; Latsis T; Hugues P; Sorel N; Cayssials E; Chomel JC; Bennaceur-Griscelli A; Turhan AG
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.
    Nieborowska-Skorska M; Kopinski PK; Ray R; Hoser G; Ngaba D; Flis S; Cramer K; Reddy MM; Koptyra M; Penserga T; Glodkowska-Mrowka E; Bolton E; Holyoake TL; Eaves CJ; Cerny-Reiterer S; Valent P; Hochhaus A; Hughes TP; van der Kuip H; Sattler M; Wiktor-Jedrzejczak W; Richardson C; Dorrance A; Stoklosa T; Williams DA; Skorski T
    Blood; 2012 May; 119(18):4253-63. PubMed ID: 22411871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.
    Kazemi-Sefat GE; Keramatipour M; Vaezi M; Razavi SM; Kavousi K; Talebi A; Rostami S; Yaghmaie M; Chahardouli B; Talebi S; Mousavizadeh K
    Sci Rep; 2022 Jul; 12(1):12816. PubMed ID: 35896598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
    Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
    Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of the induced pluripotent stem cell line KUMi001-A carrying the Philadelphia chromosome from a chronic myeloid leukemia patient.
    Kim JH; Kang KW; Lee BH; Park Y; Kim BS
    Stem Cell Res; 2021 Aug; 55():102464. PubMed ID: 34280890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.
    Toofan P; Busch C; Morrison H; O'Brien S; Jørgensen H; Copland M; Wheadon H
    Cell Death Dis; 2018 Sep; 9(9):927. PubMed ID: 30206237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Rare Chromosome Abnormality with der(16)t(1;16)(q12;q11.2) in Blast Crisis of Chronic Myeloid Leukemia.
    Yanagiya R; Ishikawa D; Toubai T; Ichikawa T; Kawaguchi N; Sugasawa K; Ishizawa K; Saito S
    Case Rep Oncol; 2020; 13(2):1020-1025. PubMed ID: 32999666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic mechanisms of chronic myeloid leukemia blastic transformation.
    Skorski T
    Curr Hematol Malig Rep; 2012 Jun; 7(2):87-93. PubMed ID: 22328017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
    Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.
    Miyauchi M; Koya J; Arai S; Yamazaki S; Honda A; Kataoka K; Yoshimi A; Taoka K; Kumano K; Kurokawa M
    Stem Cell Reports; 2018 Mar; 10(3):1115-1130. PubMed ID: 29429960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.
    Bedel A; Pasquet JM; Lippert E; Taillepierre M; Lagarde V; Dabernat S; Dubus P; Charaf L; Beliveau F; de Verneuil H; Richard E; Mahon FX; Moreau-Gaudry F
    PLoS One; 2013; 8(8):e71596. PubMed ID: 24058405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Instability of iPSCs and Challenges in Their Clinical Applications.
    Yoshihara M; Oguchi A; Murakawa Y
    Adv Exp Med Biol; 2019; 1201():23-47. PubMed ID: 31898780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
    Tabarestani S; Movafagh A
    Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: implication of 1q12-21.
    Su XY; Wong N; Cao Q; Yu LZ; Niu C; Wickham N; Johnson PJ; Chen Z; Chen SJ
    Cancer Genet Cytogenet; 1999 Jan; 108(1):6-12. PubMed ID: 9973917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of induced pluripotent stem cell line KUMi002-A with normal karyotype from a patient with Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim JH; Kang KW; Lee BH; Park Y; Kim BS
    Stem Cell Res; 2021 Aug; 55():102465. PubMed ID: 34303284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.